Review
Copyright ©The Author(s) 2019.
World J Gastroenterol. Aug 14, 2019; 25(30): 4105-4124
Published online Aug 14, 2019. doi: 10.3748/wjg.v25.i30.4105
Table 2 Frequencies of studied cytokine SNP genotypes and significance of relationships with premalignant gastric lesions in the discussed scientific articles
Ref.SNP1Variant genotypesFrequency (%) of variant genotypes in premalignant gastric lesions vs controlPremalignant gastric lesions
[73]IL-8-4073TA145 (48.5)/144 (48.6)ChAG susceptibility
AA53 (17.7)/50 (16.9)
TA148 (49.5)/144 (48.6)IM susceptibility
AA50 (16.7)/50 (16.9)
TA140 (46.4)/144 (48.6)DYS susceptibility
AA48 (15.9)/50 (16.9)
IL-18RAP917997AGa130 (43.9)/166 (56.3)ChAG susceptibility
GG72 (24.3)/61 (20.7)
AG167 (56.4)/166 (56.3)IM susceptibility
GG57 (19.3)/61 (20.7)
AG151 (50.0)/166 (56.3)DYS susceptibility
GG66 (21.8)/61 (20.7)
IL-1Brs1143627TC152 (50.9)/144 (48.5)ChAG susceptibility
CC59 (19.7)/66 (22.2)
TC148 (49.3)/144 (48.5)IM susceptibility
CC68 (22.7)/66 (22.2)
TC158 (52.5)/144 (48.5)DYS susceptibility
CC71 (23.6)/66 (22.2)
IL-1Brs1143634CT15 (5.0)/21 (7.1)ChAG susceptibility
TT0 (0.0)/1 (0.3)
CT14 (4.7)/21 (7.1)IM susceptibility
TT0 (0.0)/1 (0.3)
CT13 (4.3)/21 (7.1)DYS susceptibility
TT0 (0.0)/1 (0.3)
IL-1Brs16944GA153 (51.2)/143 (48.2)ChAG susceptibility
AA57 (19.0)/66 (22.2)
GA147 (49.0)/143 (48.2)IM susceptibility
AA67 (22.3)/66 (22.2)
GA156 (51.6)/143 (48.2)DYS susceptibility
AA70 (23.2)/66 (22.2)
IL-4Rrs2057768AG140 (46.8)/150 (50.7)ChAG susceptibility
GG71 (23.8)/61 (20.6)
AG129 (43.1)/150 (50.7)IM susceptibility
GG80 (26.8)/61 (20.6)
AG154 (51.2)/150 (50.7)DYS susceptibility
GG59 (19.6)/61 (20.6)
IL-10rs1800896AG61 (20.4)/53 (17.9)ChAG susceptibility
GG1 (0.3)/3 (1.0)
AG53 (17.6)/53 (17.9)IM susceptibility
GG5 (1.7)/3 (1.0)
AG52 (17.3)/53 (17.9)DYS susceptibility
GG2 (0.7)/3 (1.0)
IL-32rs2015620AT135 (45.8)/133 (45.7)ChAG susceptibility
TT78 (26.4)/82 (28.2)
AT144 (48.8)/133 (45.7)IM susceptibility
TT73 (24.8)/82 (28.2)
AT151 (50.0)/133 (45.7)DYS susceptibility
TT76 (25.2)/82 (28.2)
IL-22rs1179251CGa82 (27.4)/143 (48.1)ChAG susceptibility
GGa20 (6.7)/29 (9.8)
CGa47 (15.7)/143 (48.1)IM susceptibility
GGa12 (4.0)/29 (9.8)
CG111 (36.7)/143 (48.1)DYS susceptibility
GG28 (9.3)/29 (9.8)
[75]TNF-α -308GA15 (29.4)/22 (20.4)ChAG susceptibility
AA0 (0)/3 (2.8)
IL-1B -511CT18 (35.3)/53 (49.1)ChAG susceptibility
TT3 (5.9)/13 (12.0)
IL-1RNL/215 (29.4)/32 (29.6)ChAG susceptibility
2/22 (3.9)/13 (12.0)
[76]TNF-α -308GA125 (23.4)/129 (24.2)ChAG susceptibility
AA13 (2.4)/8 (1.5)
IL10T-819CTC200 (37.5)/199 (37.3)ChAG susceptibility
CCa44 (8.2)/28 (5.2)
IL10 A-1082GAG246 (46.1)/262 (49.1)ChAG susceptibility
GG109 (20.4)/116 (21.7)
IL1A C-889TCT213 (39.9)/203 (38.0)ChAG susceptibility
TT37 (6.9)/43 (8.1)
IL1B C-511TCT205 (38.4)/230 (43.1)ChAG susceptibility
TT59 (11.0)/52 (9.7)
IL1RNAT212 (39.7)/219 (41.0)ChAG susceptibility
TT39 (7.3)/35 (6.6)
IL8T-251ATA273 (51.1)/254 (47.6)ChAG susceptibility
AA100 (18.7)/114 (21.3)
[83]IL-1B-511CTa21 (48.8)/28 (32.6)ChAG risk
CCa7 (16.3)/3 (3.5)
IL-1RN2/L21 (50.0)/46 (53.5)ChAG risk
2/28 (19.0)/10 (11.6)
[84]IL-1B 31CCC+CT70 (84.3)/21 (80.8)ChAG risk
IL-1B 31CCC+CT18 (100)/73 (80.2)moderate/severe GI risk
IL-1B 31CCC+CT22 (91.7)/69 (81.2)moderate/severe LI risk
IL-1B 511TTT+CT71 (85.5)/20 (76.9)ChAG risk
IL-1B 511TTT+CT18 (100)/73 (80.2)Moderate/severe GI risk
IL-1B 511TTT+CT22 (91.7)/69 (81.2)Moderate/severe LI risk
IL-1RN*2*1/* 2+*2/* 240 (48.2)/10 (38.5)ChAG risk
IL-1RN*2*1/* 2+*2/* 27 (38.9)/43 (51.8)Moderate/severe GI risk
IL-1RN*2*1/* 2+*2/* 212 (50.0)/38 (44.7)Moderate/severe LI risk
[87]IL-1β-511TT16 (27.6)/26 (15.8)AG risk
TC30 (51.7)/88 (53.3)
TT8 (25.8)/34 (17.7)CoAG risk
TC16 (51.6)/102 (53.1)
TT8 (34.8)/34 (15.2)IM risk
TC12 (52.2)/106 (47.5)
IL-1β+3954TT1 (1.7)/2 (1.2)AG risk
TC33 (56.9)/77 (46.7)
TT0 (0.0)/3 (1.6)CoAG risk
TC19 (61.3)/91 (47.4)
TTa0 (0.0)/3 (1.3)IM risk
TCa18 (78.2)/92 (41.2)
IL-1RN intron22/213 (22.4)/20 (12.1)AG risk
2/L18 (31.0)/49 (29.7)
2/29 (29.0)/24 (12.5)CoAG risk
2/L8 (25.8)/59 (30.7)
2/2a8 (34.8)/25 (11.2)IM risk
2/L5 (21.7)/62 (27.8)
IL-10 -1082AA35 (60.3)/81 (49.1)AG risk
GA17 (29.3)/56 (33.9)
AA17 (54.8)/99 (51.6)CoAG risk
GA10 (32.3)/63 (32.8)
AA12 (52.2)/104 (46/6)IM risk
GA10 (43.5)/63 (28.3)
IL-10 -592AA8 (13.8)/12 (7.3)AG risk
CA19 (32.8)/58 (35.1)
AA4 (12.9)/16 (8.3)CoAG risk
CA10 (32.3)/67 (34.9)
AA4 (17.4)/16 (7.2)IM risk
CA8 (34.8)/69 (30.9)
[96]IL4–590CT111 (38.4)/414 (38.2)AG risk
CC134 (46.3)/506 (46.7)
IL4–590CT197 (36.2)/414 (38.2)IM risk
CC264 (48.6)/506 (46.7)
IL4–590CT48 (40.7)/414 (38.2)DYS risk
CC51 (43.2)/506 (46.7)
IL4R–3223CT96 (33.2)/362 (33.4)AG risk
CC22 (7.6)/74 (6.8)
IL4R–3223CT175 (32.2)/362 (33.4)IM risk
CC36 (6.6)/74 (6.8)
IL4R–3223CT42 (35.6)/362 (33.4)DYS risk
CC6 (5.1)/74 (6.8)
IL4R-398AG128 (44.3)/488 (45.1)AG risk
GGa71 (24.6)/201 (18.6)
AG243 (44.8)/488 (45.1)IM risk
GG106 (19.5)/201 (18.6)
AG49 (41.5)/488 (45.1)DYS risk
GG26 (22.0)/201 (18.6)
IL10–1082AG102 (35.3)/406 (37.5)AG risk
AA142 (49.1)/508 (46.9)
AG201 (37.0)/406 (37.5)IM risk
AA274 (50.5)/508 (46.9)
AGa51 (43.2)/406 (37.5)DYS risk
AAa60 (50.8)/508 (46.9)
[101]IL-6GC26 (46%)/27 (48%)ChG9
CC5 (9%)/6 (11%)
[102]IL-8 -251AAa26 (12.1%)/22 (8.7%)AG risk
AT99 (46.0%)/105 (41.7%)
IL-1B -511TT46 (21.4%)/49 (19.6%)AG risk
CT104 (48.4%)/133 (53.2%)
IL-1RN2/20 (40%)/2 (0.8%)AG risk
2/L17 (8.2%)/21 (8.8%)
[103]IL-8-251TA70 (52.2)/64 (46.7)Severe ChAG risk
AAa25 (18.7)/14 (10.2)
TAa65 (64.4)/64 (46.7)IM susceptibility
AA11 (10.9)/14 (10.2)
[106]IL-10-1082AG15 (12.9)/18 (7.8)AG susceptibility
GG0 (0)/1 (0.4)
IL-10-819CT47 (40.5)/104 (44.8)AG susceptibility
CC28 (24.1)/36 (15.5)
IL-10-592AC46 (39.7)/96 (41.4)AG susceptibility
CC31 (26.7)/52 (22.4)
[108]IL-6-174GC47 (35.9)/13 (34.2)Gastritis
CC14 (10.7)/2 (5.3)
IL-8-251TA67 (51.1)/20 (52.6)Gastritis
AA29 (22.1)/7 (18.4)
IL-10-819CT55 (41.9)/21 (55.3)Gastritis
TT10 (7.6)/6 (15.8)
IL-6-174GC22 (44.9)/13 (34.2)Peptic ulcer
CC3 (6.1)/2 (5.3)
IL-8-251TA27 (55.1)/20 (52.6)Peptic ulcer
AA15 (30.6)/7 (18.4)
IL-10-819CT21 (42.9)/21 (55.3)
TT5 (10.2)/6 (15.8)
TT5 (10.2)/6 (15.8)
[111]IL-1B-511CT67 (54.5)/88 (49.2)IM susceptibility
TT34 (27.6)/40 (22.3)